Early Development Approaches to De-Risk Complex Oral Solid Dosage Formulations

As oral solid dosage (OSD) development becomes increasingly complex, early formulation decisions are critical to reducing risk, accelerating clinical timelines, and ensuring long-term scalability.

This whitepaper explores the challenges of developing complex OSD products, including poorly soluble compounds, highly potent APIs, and modified-release formulations. Discover how Corealis Pharma's integrated approach to formulation development, analytical testing, process optimization, and GMP clinical manufacturing helps pharmaceutical and biotechnology companies minimize development risks, improve efficiency, and establish a stronger foundation for successful clinical development and future commercial manufacturing.